AU2002227912A1 - Repinotan kit - Google Patents

Repinotan kit

Info

Publication number
AU2002227912A1
AU2002227912A1 AU2002227912A AU2791202A AU2002227912A1 AU 2002227912 A1 AU2002227912 A1 AU 2002227912A1 AU 2002227912 A AU2002227912 A AU 2002227912A AU 2791202 A AU2791202 A AU 2791202A AU 2002227912 A1 AU2002227912 A1 AU 2002227912A1
Authority
AU
Australia
Prior art keywords
repinotan
kit
repinotan kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002227912A
Other languages
English (en)
Inventor
Werner Kroll
Maria-Luisa Rodriguez
Ferdinand Rombout
Rudolf Schohe-Loop
Bernd Sennhenn
Horst Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2002227912A1 publication Critical patent/AU2002227912A1/en
Assigned to BAYER HEALTHCARE AG reassignment BAYER HEALTHCARE AG Request for Assignment Assignors: BAYER ATKIENGESELLSCHAFT
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002227912A 2000-11-22 2001-11-09 Repinotan kit Abandoned AU2002227912A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10058119.6 2000-11-22
DE10058119A DE10058119A1 (de) 2000-11-22 2000-11-22 Pepinotan-Kit
PCT/EP2001/012968 WO2002041881A2 (de) 2000-11-22 2001-11-09 Repinotan-kit

Publications (1)

Publication Number Publication Date
AU2002227912A1 true AU2002227912A1 (en) 2002-06-03

Family

ID=7664358

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002227912A Abandoned AU2002227912A1 (en) 2000-11-22 2001-11-09 Repinotan kit

Country Status (37)

Country Link
US (2) US6605255B2 (xx)
EP (1) EP1339403B1 (xx)
JP (2) JP2004517824A (xx)
KR (1) KR20030096237A (xx)
CN (2) CN1518446A (xx)
AR (1) AR031761A1 (xx)
AT (1) ATE284212T1 (xx)
AU (1) AU2002227912A1 (xx)
BG (1) BG107803A (xx)
BR (1) BR0115518A (xx)
CA (1) CA2429310A1 (xx)
CZ (1) CZ20031401A3 (xx)
DE (2) DE10058119A1 (xx)
DO (1) DOP2001000293A (xx)
EC (1) ECSP034617A (xx)
EE (1) EE200300242A (xx)
ES (1) ES2234922T3 (xx)
GT (1) GT200100236A (xx)
HN (1) HN2001000262A (xx)
HR (1) HRP20030490A2 (xx)
HU (1) HUP0303294A2 (xx)
IL (1) IL155975A0 (xx)
MA (1) MA26059A1 (xx)
MX (1) MXPA03004499A (xx)
MY (1) MY118345A (xx)
NO (1) NO20032212D0 (xx)
NZ (1) NZ525964A (xx)
PE (1) PE20020533A1 (xx)
PL (1) PL361628A1 (xx)
PT (1) PT1339403E (xx)
RU (1) RU2003118583A (xx)
SI (1) SI1339403T1 (xx)
SK (1) SK5922003A3 (xx)
SV (1) SV2003000744A (xx)
UY (1) UY27027A1 (xx)
WO (1) WO2002041881A2 (xx)
ZA (1) ZA200303888B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE19522088A1 (de) * 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19543476A1 (de) * 1995-11-22 1997-05-28 Troponwerke Gmbh & Co Kg Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE19754573A1 (de) * 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
CA2324096A1 (en) * 1998-03-10 1999-09-16 Strategic Diagnostics, Inc. Integrated assay device and methods of production and use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19936281C2 (de) 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung

Also Published As

Publication number Publication date
US20030060493A1 (en) 2003-03-27
NZ525964A (en) 2006-02-24
BG107803A (bg) 2004-01-30
CN1715279A (zh) 2006-01-04
SV2003000744A (es) 2003-01-13
DE10058119A1 (de) 2002-05-23
MY118345A (en) 2004-10-30
EP1339403A2 (de) 2003-09-03
JP2004517824A (ja) 2004-06-17
US6605255B2 (en) 2003-08-12
AR031761A1 (es) 2003-10-01
ZA200303888B (en) 2004-05-20
ECSP034617A (es) 2003-06-25
ES2234922T3 (es) 2005-07-01
DOP2001000293A (es) 2002-03-15
WO2002041881A2 (de) 2002-05-30
NO20032212L (no) 2003-05-15
SI1339403T1 (en) 2005-04-30
GT200100236A (es) 2002-06-25
PT1339403E (pt) 2005-03-31
JP2005232189A (ja) 2005-09-02
HUP0303294A2 (en) 2007-09-28
PL361628A1 (en) 2004-10-04
MXPA03004499A (es) 2004-05-14
US20030203953A1 (en) 2003-10-30
EP1339403B1 (de) 2004-12-08
KR20030096237A (ko) 2003-12-24
DE50104790D1 (de) 2005-01-13
MA26059A1 (fr) 2004-04-01
ATE284212T1 (de) 2004-12-15
RU2003118583A (ru) 2004-12-20
IL155975A0 (en) 2003-12-23
EE200300242A (et) 2003-10-15
SK5922003A3 (en) 2003-11-04
CZ20031401A3 (cs) 2003-10-15
CN1518446A (zh) 2004-08-04
NO20032212D0 (no) 2003-05-15
HRP20030490A2 (hr) 2005-06-30
HN2001000262A (es) 2002-01-30
BR0115518A (pt) 2003-09-16
WO2002041881A3 (de) 2002-10-10
CA2429310A1 (en) 2002-05-30
UY27027A1 (es) 2002-07-31
PE20020533A1 (es) 2002-07-13

Similar Documents

Publication Publication Date Title
AUPQ496500A0 (en) Kit
AU2001259665A1 (en) Prioritized first aid kit
AU2001288610A1 (en) Feminine hygiene kit
AU2000267458A1 (en) Hypercomputer
AU2001288040A1 (en) Homeostasis-maintaining agents
AU2002214284A1 (en) Anti-helicobacterial agents
AU2002227912A1 (en) Repinotan kit
AU2001220246A1 (en) Neckphone
AU2001258924A1 (en) Microsatellite-aflp
EP1203966A3 (en) Position determination
AU2001237694A1 (en) Extension kit for calipers
AU2002223788A1 (en) Tannages
AU2001227147A1 (en) Pin kit for v-cutter
AU4620300A (en) Can
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001262711A1 (en) Cytoprotectors
AU2002219846A1 (en) Novel use
AU2001274683A1 (en) Contrast agents
AU2001282360A1 (en) Kit of adhesion-release agents
AU2001251113A1 (en) Monooxygenase assays
AU2001256287A1 (en) 2-phenyl-2h-pyridazine-3-ones
AU6759601A (en) Well
AU2002216349A1 (en) Potty kit
AU2002210437A1 (en) Organizer
AU2001277537A1 (en) Agents

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application